Abstract
Vaccine dose-response curves can follow both saturating and peaking shapes. Dose-response curves for adenoviral vector vaccines have not been systematically described. In this paper, we explore the dose-response shape of published adenoviral animal and human studies. Where data were informative, dose-response was approximately five times more likely to be peaking than saturating. There was evidence that host species and response type may be sufficient for prediction of dose-response curve shape. Dose-response curve shape prediction could decrease clinical trial costs, accelerating the development of life-saving vaccines.
Funder
Biotechnology and Biological Sciences Research Council
Medical Research Council
Department for International Development
Bill and Melinda Gates Foundation
Economic and Social Research Council
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology